We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Friendly does it

27 August 2010 By Pierre Briancon

The French pharma group is understandably cautious in its approach to Genzyme. It needs access the books to get a full understanding of industrial problems that have plagued the U.S. biotech. Only with that cooperation could Sanofi improve its $18 bln offer within limits.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)